Cargando…

Mid-term clinical results of chronic cavitary long bone osteomyelitis treatment using S53P4 bioactive glass: a multi-center study

Introduction: Chronic osteomyelitis is a challenging condition in the orthopedic practice and traditionally treated using local and systemic antibiotics in a two-stage surgical procedure. With the introduction of the antimicrobial biomaterial S53P4 bioactive glass (Bonalive(®)), chronic osteomyeliti...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Vugt, Tom A. G., Heidotting, Jeffrey, Arts, Jacobus J., Ploegmakers, Joris J. W., Jutte, Paul C., Geurts, Jan A. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Copernicus GmbH 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600462/
https://www.ncbi.nlm.nih.gov/pubmed/34804776
http://dx.doi.org/10.5194/jbji-6-413-2021
_version_ 1784601159982383104
author Van Vugt, Tom A. G.
Heidotting, Jeffrey
Arts, Jacobus J.
Ploegmakers, Joris J. W.
Jutte, Paul C.
Geurts, Jan A. P.
author_facet Van Vugt, Tom A. G.
Heidotting, Jeffrey
Arts, Jacobus J.
Ploegmakers, Joris J. W.
Jutte, Paul C.
Geurts, Jan A. P.
author_sort Van Vugt, Tom A. G.
collection PubMed
description Introduction: Chronic osteomyelitis is a challenging condition in the orthopedic practice and traditionally treated using local and systemic antibiotics in a two-stage surgical procedure. With the introduction of the antimicrobial biomaterial S53P4 bioactive glass (Bonalive(®)), chronic osteomyelitis can be treated in a one-stage procedure. This study evaluated the mid-term clinical results of patients treated with S53P4 bioactive glass for long bone chronic osteomyelitis. Methods: In this prospective multi-center study, patients from two different university medical centers in the Netherlands were included. One-stage treatment consisted of debridement surgery, implantation of S53P4 bioactive glass, and treatment with culture-based systemic antibiotics. If required, wound closure by a plastic surgeon was performed. The primary outcome was the eradication of infection, and a secondary statistical analysis was performed on probable risk factors for treatment failure. Results: In total, 78 patients with chronic cavitary long bone osteomyelitis were included. Follow-up was at least 12 months (mean 46; standard deviation, SD, 20), and 69 patients were treated in a one-stage procedure. Overall infection eradication was 85 %, and 1-year infection-free survival was 89 %. Primary closure versus local/muscular flap coverage is the only risk factor for treatment failure. Conclusion: With 85 % eradication of infection, S53P4 bioactive glass is an effective biomaterial in the treatment of chronic osteomyelitis in a one-stage procedure. A major risk factor for treatment failure is the necessity for local/free muscle flap coverage. These results confirm earlier published data, and together with the fundamentally different antimicrobial pathways without antibiotic resistance, S53P4 bioactive glass is a recommendable biomaterial for chronic osteomyelitis treatment and might be beneficial over other biomaterials.
format Online
Article
Text
id pubmed-8600462
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Copernicus GmbH
record_format MEDLINE/PubMed
spelling pubmed-86004622021-11-19 Mid-term clinical results of chronic cavitary long bone osteomyelitis treatment using S53P4 bioactive glass: a multi-center study Van Vugt, Tom A. G. Heidotting, Jeffrey Arts, Jacobus J. Ploegmakers, Joris J. W. Jutte, Paul C. Geurts, Jan A. P. J Bone Jt Infect Original Full-Length Article Introduction: Chronic osteomyelitis is a challenging condition in the orthopedic practice and traditionally treated using local and systemic antibiotics in a two-stage surgical procedure. With the introduction of the antimicrobial biomaterial S53P4 bioactive glass (Bonalive(®)), chronic osteomyelitis can be treated in a one-stage procedure. This study evaluated the mid-term clinical results of patients treated with S53P4 bioactive glass for long bone chronic osteomyelitis. Methods: In this prospective multi-center study, patients from two different university medical centers in the Netherlands were included. One-stage treatment consisted of debridement surgery, implantation of S53P4 bioactive glass, and treatment with culture-based systemic antibiotics. If required, wound closure by a plastic surgeon was performed. The primary outcome was the eradication of infection, and a secondary statistical analysis was performed on probable risk factors for treatment failure. Results: In total, 78 patients with chronic cavitary long bone osteomyelitis were included. Follow-up was at least 12 months (mean 46; standard deviation, SD, 20), and 69 patients were treated in a one-stage procedure. Overall infection eradication was 85 %, and 1-year infection-free survival was 89 %. Primary closure versus local/muscular flap coverage is the only risk factor for treatment failure. Conclusion: With 85 % eradication of infection, S53P4 bioactive glass is an effective biomaterial in the treatment of chronic osteomyelitis in a one-stage procedure. A major risk factor for treatment failure is the necessity for local/free muscle flap coverage. These results confirm earlier published data, and together with the fundamentally different antimicrobial pathways without antibiotic resistance, S53P4 bioactive glass is a recommendable biomaterial for chronic osteomyelitis treatment and might be beneficial over other biomaterials. Copernicus GmbH 2021-11-12 /pmc/articles/PMC8600462/ /pubmed/34804776 http://dx.doi.org/10.5194/jbji-6-413-2021 Text en Copyright: © 2021 Tom A. G. Van Vugt et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/
spellingShingle Original Full-Length Article
Van Vugt, Tom A. G.
Heidotting, Jeffrey
Arts, Jacobus J.
Ploegmakers, Joris J. W.
Jutte, Paul C.
Geurts, Jan A. P.
Mid-term clinical results of chronic cavitary long bone osteomyelitis treatment using S53P4 bioactive glass: a multi-center study
title Mid-term clinical results of chronic cavitary long bone osteomyelitis treatment using S53P4 bioactive glass: a multi-center study
title_full Mid-term clinical results of chronic cavitary long bone osteomyelitis treatment using S53P4 bioactive glass: a multi-center study
title_fullStr Mid-term clinical results of chronic cavitary long bone osteomyelitis treatment using S53P4 bioactive glass: a multi-center study
title_full_unstemmed Mid-term clinical results of chronic cavitary long bone osteomyelitis treatment using S53P4 bioactive glass: a multi-center study
title_short Mid-term clinical results of chronic cavitary long bone osteomyelitis treatment using S53P4 bioactive glass: a multi-center study
title_sort mid-term clinical results of chronic cavitary long bone osteomyelitis treatment using s53p4 bioactive glass: a multi-center study
topic Original Full-Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600462/
https://www.ncbi.nlm.nih.gov/pubmed/34804776
http://dx.doi.org/10.5194/jbji-6-413-2021
work_keys_str_mv AT vanvugttomag midtermclinicalresultsofchroniccavitarylongboneosteomyelitistreatmentusings53p4bioactiveglassamulticenterstudy
AT heidottingjeffrey midtermclinicalresultsofchroniccavitarylongboneosteomyelitistreatmentusings53p4bioactiveglassamulticenterstudy
AT artsjacobusj midtermclinicalresultsofchroniccavitarylongboneosteomyelitistreatmentusings53p4bioactiveglassamulticenterstudy
AT ploegmakersjorisjw midtermclinicalresultsofchroniccavitarylongboneosteomyelitistreatmentusings53p4bioactiveglassamulticenterstudy
AT juttepaulc midtermclinicalresultsofchroniccavitarylongboneosteomyelitistreatmentusings53p4bioactiveglassamulticenterstudy
AT geurtsjanap midtermclinicalresultsofchroniccavitarylongboneosteomyelitistreatmentusings53p4bioactiveglassamulticenterstudy